A recent study by Michaelson et al. showed possible improvement of chemoradiation response with erbB2 targeted therapy [28]; 66 evaluable bladder cancer patients were treated with radiation (64.8 Gy) and either paclitaxel + anti-erbB2 monoclonal antibody, trastuzumab (group 1, n = 20) or paclitaxel alone (group 2, n = 46) according to the presence (group 1) or absence of erbB2 overexpression (group 2) in tumor tissues. The gene discussed is ERBB2; the disease is urinary bladder carcinoma.